An observational study in Carbon Monoxide Poisoning, Myocardial Injury and Neurologic Deficits, sponsored by Wonju Severance Christian Hospital. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Wonju Severance Christian Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective cohort study enrolls subjects who experience carbon monoxide (CO) poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments and short and long-term outcomes in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through various ways and the association between complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.
This prospective cohort study enrolls subjects who experience CO poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments, including hyperbaric oxygen therapy (HBO), therapeutic hypothermia (TH), and additional drugs, and short and long-term outcomes, such as neurocognitive sequelae or mortality, in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through a variety of ways, such as magnetic resonance image (MRI), computed tomography (CT), ultrasound, and laboratory test, and the association between various complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.
44 studies on the registry are indexed under Carbon Monoxide Poisoning; 8 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 104 across 25 observational studies indexed under Carbon Monoxide Poisoning.
Browse Carbon Monoxide Poisoning studies →Wonju Severance Christian Hospital is the lead sponsor of 43 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Acute CO poisoning
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin \>5% (\>10% in smokers).
Diagnostic Test: Cardiac MRI · Procedure: Hyperbaric oxygen therapy
1. Cardiac MRI be taken to CO poisoned patients 2. Cardiac CT be taken to CO poisoned patients 3. TTE be taken to CO poisoned patients 4. Brain MRI be taken to CO poisoned patients 5. Neurocognitive function tests be taken to CO poisoned patients 6. Laboratory tests be taken to CO poisoned patients
Also known as: Cardiac CT, Transthoracic echocardiography (TTE), Brain MRI, Neurocognitive function tests, Laboratory tests
1. Hyperbaric oxygen therapy be used for CO poisoned patients 2. Therapeutic hypothermia be used for CO poisoned patients
Also known as: Therapeutic hypothermia
Therapeutic response to HBO at 1 month
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 1 month after CO exposure
Time frame: At 1 month after CO exposure
Therapeutic response to HBO at 6 months
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 6 months after CO exposure
Time frame: At 6 months after CO exposure
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as neurocognitive function tests
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Time frame: Within 1 month after CO exposure
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as neurocognitive function tests
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Time frame: Within 1 month after CO exposure
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as neurocognitive function tests
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Time frame: Within 1 month after CO exposure
Therapeutic response to HBO at 12 months
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 12 months after CO exposure
Time frame: At 12 months after CO exposure
Therapeutic response to TH combined with HBO at 1 month
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 1 month after CO exposure
Time frame: At 1 month after CO exposure
Therapeutic response to TH combined with HBO at 6 months
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 6 months after CO exposure
Time frame: At 6 months after CO exposure
Therapeutic response to TH combined with HBO at 12 months
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 12 months after CO exposure
Time frame: At 12 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 1 month
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 1 month after CO exposure
Time frame: At 1 month after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 6 months
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 6 months after CO exposure
Time frame: At 6 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 12 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 12 months after CO exposure
Time frame: At 12 months after CO exposure
Cardiac injury evaluated by cardiac MRI in acute phase
Cardiac injury related to CO poisoning evaluated by cardiac MRI in acute phase
Time frame: Within 1 month after CO exposure
Cardiac injury evaluated by cardiac MRI in chronic phase
Cardiac injury related to CO poisoning evaluated by cardiac MRI in chronic phase
Time frame: Follow-up cardiac MRI (at 4-8 months after CO exposure)
Cardiac injury evaluated by cardiac CT
Cardiac injury evaluated by cardiac CT in CO poisoning
Time frame: Within 1 month after CO exposure
Cardiac injury evaluated by TTE in acute phase
Cardiac injury related to CO poisoning evaluated by TTE in acute phase
Time frame: Within 14 days after CO exposure
Cardiac injury evaluated by TTE in chronic phase
Cardiac injury related to CO poisoning evaluated by TTE in chronic phase
Time frame: Within 4-8 months after CO exposure
Brain injury evaluated by brain imaging modality related to CO poisoning
Brain injury evaluated by brain MRI in CO poisoning
Time frame: Within 6 months after CO exposure
Brain injury related to CO poisoning
Brain injury evaluated by laboratory tests in CO poisoning
Time frame: Within 6 months after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure
Time frame: Outcomes at 1 month after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure
Time frame: Outcomes at 6 months after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure
Time frame: Outcomes at 12 months after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure
Time frame: Outcomes at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 1 month after CO exposure
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 6 months after CO exposure
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 12 months after CO exposure
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 1 month after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 6 months after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 12 months after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc
Time frame: Outcomes at 5 years after CO exposure
Therapeutic response to drugs at 1 month
Therapeutic response to additional drug including steroid at 1 month after CO exposure
Time frame: At 1 month after CO exposure
Therapeutic response to drugs at 6 months
Therapeutic response to additional drug including steroid at 6 months after CO exposure
Time frame: At 6 months after CO exposure
Therapeutic response to drugs at 12 months
Therapeutic response to additional drug including steroid at 12 months after CO exposure
Time frame: At 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 1 month
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 1 month after CO exposure
Time frame: At 1 month after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 6 months
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 6 months after CO exposure
Time frame: At 6 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 12 months
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 12 months after CO exposure
Time frame: At 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 5 years
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 5 years after CO exposure
Time frame: At 5 years after CO exposure
Organ injury related to CO poisoning
Organ injury, such as lung, kidney, liver, pancreas, or bowel, etc, related to CO poisoning
Time frame: Within 6 months after CO exposure
Complications related to CO poisoning
Complications, such as pulmonary thromboembolism or rhabdomyolysis, etc, related to CO poisoning
Time frame: Within 6 months after CO exposure
Effect of HBO for delayed neurocognitive and psychological dysfunction at 1 year after onset
Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 1 year after sequelae onset
Time frame: Within 1 year after delayed neurocognitive and psychological sequelae onset
Effect of HBO for delayed neurocognitive and psychological dysfunction at 2 years after onset
Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 2 years after sequelae onset
Time frame: Within 2 years after delayed neurocognitive and psychological sequelae onset
Validation of methods evaluating neurocognitive and psychological outcomes
Validation of methods evaluating neurocognitive and psychological outcomes within 6 months
Time frame: Within 6 months after CO exposure
Started Jul 2020 (actual). Primary completion is estimated for Dec 2030, 125 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wonju Severance Christian Hospital